文献速递介入腹部US

供血血管消融:一种治疗位于肝脏边缘角肝细胞癌的新型亚段去血管化技术

Feeding Vessel Ablation: A Novel Subsegmental Devascularization Technique for the Treatment of Hepatocellular Carcinoma Located at the Liver Marginal Angle.
PubMed 文献 · Ultrasound Med Biol · 2021-12-28

这项前瞻性先导临床研究纳入9例位于肝脏边缘角(2/3/6段)且邻近胃肠道的不可切除肝细胞癌病灶,在人工腹水尝试失败后,用多模态超声识别供血血管并以单极冷循环电极行供血血管消融。消融后即刻技术成功率为7/9(77.8%),1个月评估7/7肿瘤(100%)达完全缓解;中位随访15.6个月期间6/7(85.7%)维持完全缓解,1/7(14.3%)于治疗后4.7个月出现局部肿瘤进展,无主要并发症。作者认为供血血管消融可诱导亚段去血管化,当人工腹水失败时可能作为位于肝脏边缘角不可切除肝细胞癌局部控制的一种有效且安全的替代技术。

要点

  • 位于肝脏边缘角(2/3/6段)且邻近胃肠道的不可切除肝细胞癌,在人工腹水失败后可行供血血管消融。
  • 用二维及实时三维超声造影识别供血血管走行,将消融靶点置于亚段或更远端血管以诱导下游缺血区。
  • 消融后即刻技术成功7/9(77.8%),1个月完全缓解7/7(100%),随访中局部肿瘤进展1/7(14.3%)。

核心结论

  • 作者认为供血血管消融可诱导亚段去血管化,当人工腹水失败时可能作为位于肝脏边缘角不可切除肝细胞癌局部控制的一种有效且安全的替代技术。

研究设计与样本

  • 前瞻性先导临床研究,纳入9例患者共9个不可切除肝细胞癌病灶(平均3.0 cm,四分位距2.4–3.6 cm),位于肝脏边缘角(2/3/6段)且邻近胃肠道,人工腹水尝试均失败。

关键影像表现/征象

  • 采用二维超声及实时三维超声造影识别目标肿瘤供血血管的形态与结构。
  • 治疗中使用单极冷循环电极消融供血血管,消融靶点设于亚段或更远端血管以诱导下游缺血区。

诊断标准与关键数值

  • 消融后即刻技术成功率为7/9(77.8%)。
  • 1个月评估时完全缓解为7/7(100%)。
  • 中位随访15.6个月(范围4.3–53.3个月)期间,完全缓解维持6/7(85.7%),局部肿瘤进展1/7(14.3%),于治疗后4.7个月出现。
  • 累积1年、3年、5年无局部肿瘤进展率均为83.3%;累积1年、3年、5年总生存率分别为42.9%、28.6%和0%。
  • 未发生主要并发症。

临床应用与阅片要点

  • 对位于肝脏边缘角(2/3/6段)且邻近胃肠道的不可切除肝细胞癌,人工腹水失败时可考虑供血血管消融(原文结论为 has the potential to serve as an effective and safe alternative technique)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

This pilot clinical study evaluated primarily the efficacy of feeding vessel ablation (FVA) in the treatment of hepatocellular carcinoma (HCC) located at the liver marginal angle (LMA). Nine patients with nine unresectable HCC lesions were prospectively included in this study. The target tumors (mean: 3.0 cm, interquartile range: 2.4-3.6 cm) were located at the LMA (segment 2/3/6) and adjacent to the gastrointestinal tract. Artificial ascites was attempted and failed. Multimode ultrasound technologies, including 2-D and real-time 3-D contrast-enhanced ultrasound, were used to identify the morphology and structure of the feeding vessels for the target tumors. During the treatment, a unipolar cool-tip electrode was used to ablate the feeding vessels, and the target ablation point was set in subsegmental or more distal vessels to induce a downstream ischemia region. Therapeutic outcomes were assessed after FVA, including the rates of technical success, tumor response, local tumor progression (LTP), overall survival (OS) and major complications. Cumulative LTP and OS were estimated with the Kaplan-Meier method. The technical success rate determined immediately after radiofrequency ablation was 7 of 9 (77.8%). Complete response (CR) was achieved in 7 of 7 tumors (100%) at the 1-mo evaluation. During a median follow-up period of 15.6 mo (range: 4.3-53.3 mo), CR remained in 6 of 7 tumors (85.7%), with LTP observed in 1 of 7 tumors (14.3%) 4.7 mo after treatment. The cumulative 1-, 3- and 5-y LTP-free rates were all 83.3%, and the cumulative 1-, 3- and 5-y OS rates were 42.9%, 28.6% and 0%, respectively. No major complications occurred. We concluded that FVA can induce subsegmental devascularization and has the potential to serve as an effective and safe alternative technique for local control of unresectable HCC located at the LMA when artificial ascites fails.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Li, Zhang, Shi, et al. Feeding Vessel Ablation: A Novel Subsegmental Devascularization Technique for the Treatment of Hepatocellular Carcinoma Located at the Liver Marginal Angle. Ultrasound Med Biol. 2021. PMID: 34972571. doi:10.1016/j.ultrasmedbio.2021.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。